Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

The old Eli Lilly logo on the side of a building. Despite strong growth drivers, Eli Lilly’s stock faces challenges. With a forward earnings multiple above 65-times and a PEG ratio of 2.5 ...

Eli Lilly stock could prove to be a no-brainer buy right now. It has been a strong start to the year for Eli Lilly on news of its recent trial data on orforglipron.

Below, I'll make the case for why pharma giant Eli Lilly still looks like a great buy right now -- even though it trades at a P/E of more than 70 -- and why selling the healthcare stock could be a ...

From a valuation perspective, LLY stock looks appropriately priced, but the massive demand for Zepbound and Mounjaro may continue to bolster its stock. Looking at Q2, Eli Lilly’s revenue of $11. ...